• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Berkeley Lights Inc.

    3/9/23 4:18:46 PM ET
    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BLI alert in real time by email
    SC 13G 1 berkeley13g-030923.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G
    (RULE 13d - 102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
    (Amendment No. )*
    Berkeley Lights, Inc.
    (Name of Issuer)
    Common Stock, par value $0.00005
    (Title of Class of Securities)
    84310101
    (CUSIP Number)
    March 1, 2023
     (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐    Rule 13d-1(b)
    [x]    Rule 13d-1(c)
    ☐    Rule 13d-1(d)

    *  The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1.
    names of Reporting Persons
     
    The D3 Family Fund, L.P.
     
    2.
    check the appropriate box if a member of a group
    (a)        [x]
    (b)        ☐
    3.
    sec use only
     
    4.
    citizenship or place of organization
     
    Washington
     


    NUMBER OF
    5.
    sole voting power
    0
    SHARES
    BENEFICIALLY
    OWNED BY
    6.
    shared voting power
    1,246,164
    EACH
    REPORTING
    PERSON
    7.
    sole dispositive power
    0
    WITH
     
     
    8.
    shared dispositive power
    1,246,164
    9.
    aggregate amount beneficially owned by each reporting person
    1,246,164
    10.
    check box if the aggregate amount in row (9) excludes certain shares  ☐
     
    11.
    percent of class represented by amount in row (9)
    1.7%
    12.
    type of Reporting Person
    PN
     



    1.
    names of Reporting Persons
     
    The D3 Family Bulldog Fund, L.P.
     
    2.
    check the appropriate box if a member of a group
    (a)        [x]
    (b)        ☐
    3.
    sec use only
     
    4.
    citizenship or place of organization
     
    Washington
     


    NUMBER OF
    5.
    sole voting power
    0
    SHARES
    BENEFICIALLY
    OWNED BY
    6.
    shared voting power
    2,233,948
    EACH
    REPORTING
    PERSON
    7.
    sole dispositive power
    0
    WITH
     
     
    8.
    shared dispositive power
    2,233,948
    9.
    aggregate amount beneficially owned by each reporting person
    2,233,948
    10.
    check box if the aggregate amount in row (9) excludes certain shares  ☐
     
    11.
    percent of class represented by amount in row (9)
    3.1%
    12.
    type of Reporting Person
    PN
     



    1.
    names of Reporting Persons
     
    Haredale Ltd.
     
    2.
    check the appropriate box if a member of a group
    (a)        [x]
    (b)        ☐
    3.
    sec use only
     
    4.
    citizenship or place of organization
     
    Bahamas
     


    NUMBER OF
    5.
    sole voting power
    134,362
    SHARES
    BENEFICIALLY
    OWNED BY
    6.
    shared voting power
     
    EACH
    REPORTING
    PERSON
    7.
    sole dispositive power
    0
    WITH
     
     
    8.
    shared dispositive power
    134,362
    9.
    aggregate amount beneficially owned by each reporting person
    134,362
    10.
    check box if the aggregate amount in row (9) excludes certain shares  ☐
     
    11.
    percent of class represented by amount in row (9)
    Less than 1%
    12.
    type of Reporting Person
    CO
     



    1.
    names of Reporting Persons
     
    Nierenberg Investment Management Company, Inc.
     
    2.
    check the appropriate box if a member of a group
    (a)        [x]
    (b)        ☐
    3.
    sec use only
     
    4.
    citizenship or place of organization
     
    Washington
     


    NUMBER OF
    5.
    sole voting power
    0
    SHARES
    BENEFICIALLY
    OWNED BY
    6.
    shared voting power
    3,480,112
    EACH
    REPORTING
    PERSON
    7.
    sole dispositive power
    0
    WITH
     
     
    8.
    shared dispositive power
    3,614,474
    9.
    aggregate amount beneficially owned by each reporting person
    3,614,474
    10.
    check box if the aggregate amount in row (9) excludes certain shares  ☐
     
    11.
    percent of class represented by amount in row (9)
    5.0%
    12.
    type of Reporting Person
    CO
     



    1.
    names of Reporting Persons
     
    David Nierenberg
     
    2.
    check the appropriate box if a member of a group
    (a)        [x]
    (b)        ☐
    3.
    sec use only
     
    4.
    citizenship or place of organization
     
    United Stated of America
     


    NUMBER OF
    5.
    sole voting power
    47,600
    SHARES
    BENEFICIALLY
    OWNED BY
    6.
    shared voting power
    3,480,112
    EACH
    REPORTING
    PERSON
    7.
    sole dispositive power
    47,600
    WITH
     
     
    8.
    shared dispositive power
    3,614,474
    9.
    aggregate amount beneficially owned by each reporting person
    3,662,074
    10.
    check box if the aggregate amount in row (9) excludes certain shares  ☐
     
    11.
    percent of class represented by amount in row (9)
    5.1%
    12.
    type of Reporting Person
    IN
     


    This Schedule 13G reflects the beneficial ownership of the Reporting Persons (as defined below) as of March 1, 2023.
    Item 1.

    (a)
    Name of Issuer:
    Berkely Lights, Inc. (the “Issuer”)

    (b)
    Address of Issuer's Principal Executive Offices:
    5858 Horton Street, Emery Ville, CA 94608
    Item 2.

    (a), (c)
    Name of Person Filing and Citizenship:
    The names of the persons filing this Schedule 13G (collectively, the “Reporting Persons”) are:

    •
    The D3 Family Fund, L.P., a Washington limited partnership (the “Family Fund”);

    •
    The D3 Family Bulldog Fund, L.P., a Washington limited partnership (the “Bulldog Fund”);

    •
    Haredale Limited, a Bahamian corporation (the “Managed Account”),

    •
    Nierenberg Investment Management Company, Inc., a Washington corporation (“NIMCO”) which is the sole general partner of the Family Fund and the Bulldog Fund;

    •
    David Nierenberg, a United States citizen (“Mr. Nierenberg”), who is the President of NIMCO. 

    NIMCO and Mr. Nierenberg may each be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) held by the Family Fund and the Bulldog Fund.


    (b)
    Address of Principal Business Office or, if None, Residence:
    The business address of each of the Reporting Persons is 19605 N.E. 8th Street, Camas, Washington 98607.

    (d)
    Title of Class of Securities:  Common Stock, $0.0005 par value (the “Common Stock”)

    (e)
    CUSIP Number: 84310101
    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:  N/A

    (a)             ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

    (b)             ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)             ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)             ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e)             ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);



    (f)             ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g)             ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h)             ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)             ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)             ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

    (k)             ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in        accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____.
    If this statement is filed pursuant to Rule 13d-1(c), check this box [x]
    Item 4.
    Ownership.

    (a), (b)
    Amount beneficially owned; Percent of Class:
    The Family Fund individually beneficially owns 1,246,164 shares of Common Stock, constituting approximately 1.7% of all of the outstanding shares of Common Stock.
    The Bulldog Fund individually beneficially owns 2,233,948 shares of Common Stock, constituting approximately 3.1% of all of the outstanding shares of Common Stock.
    NIMCO may be deemed to be the beneficial owner of the 3,614,474 shares of Common Stock owned by the Family Fund, the Bulldog Fund, the Benedict Fund and the Managed Account, constituting approximately 5.0% of all of the outstanding shares of Common Stock.
    Mr. Nierenberg may be deemed to be the beneficial owner of the 3,614,474 shares of Common Stock beneficially owned by NIMCO as well as the 47,600 shares of Common Stock that he holds directly, for a total of 3,662,074 shares of Common Stock, constituting approximately 5.1% of all of the outstanding shares of Common Stock.
    The Reporting Persons, in the aggregate, beneficially own 3,662,074 shares of Common Stock, constituting approximately 5.1% of the outstanding shares of Common Stock. The foregoing percentages are based on 72,173,917 shares of Common Stock outstanding as of February 14, 2023, as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2023.

    (c)
    Number of shares as to which such person has:
    (i), (iii)                          The Managed Account has the sole power to vote or direct the vote of the Common Stock held by it. None of the Reporting Persons has the sole power to dispose or direct the disposition of, any shares of Common Stock.
    (ii), (iv)                          The Family Fund, NIMCO and Mr. Nierenberg have shared power (A) to vote or direct the vote of, and (B) to dispose or direct the disposition of, the 1,246,164 shares of Common Stock held by the Family Fund.

    The Bulldog Fund, NIMCO and Mr. Nierenberg have shared power (A) to vote or direct the vote of, and (B) to dispose or direct the disposition of, the 2,233,948 shares of Common Stock held by the Bulldog Fund.
    The Managed Account, NIMCO and Mr. Nierenberg have shared power to dispose or direct the disposition of, the 134,362 shares of Common Stock held by the Bulldog Fund.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    N/A
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
    N/A
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit 1.
    Item 9.
    Notice of Dissolution of Group.
    N/A
    Item 10.
    Certification.
    By signing below each of the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in the Statement is true, complete and correct.

    Dated:  March 9, 2023

    D3 FAMILY FUND, L.P.*
    By: Nierenberg Investment Management Company, Inc.,
    its General Partner
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    D3 FAMILY BULLDOG FUND, L.P.*
    By: Nierenberg Investment Management Company, Inc.,
    its General Partner
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    HAREDALE LTD.*
    By: Nierenberg Investment Management Company, Inc.,
    its Investment Manager
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    NIERENBERG INVESTMENT MANAGEMENT COMPANY, INC.*
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    /s/ David Nierenberg
     
    DAVID NIERENBERG*
     

    *The Reporting Persons disclaim beneficial ownership in the shares of Common Stock reported herein except to the extent of their pecuniary interest therein.
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
    Note.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.
    Attention.  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).


    EXHIBIT 1

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Berkeley Lights, Inc, dated as of March 9, 2023, is, and any further amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.

    Dated:  March 9, 2023

    D3 FAMILY FUND, L.P.
    By: Nierenberg Investment Management Company, Inc.,
    its General Partner
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    D3 FAMILY BULLDOG FUND, L.P.
    By: Nierenberg Investment Management Company, Inc.,
    its General Partner
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    HAREDALE LTD.
    By: Nierenberg Investment Management Company, Inc.,
    its Investment Manager
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    NIERENBERG INVESTMENT MANAGEMENT COMPANY, INC.
     
       
    By:
    /s/ David Nierenberg
     
     
    David Nierenberg, President
     

    /s/ David Nierenberg
     
    DAVID NIERENBERG
     



    Get the next $BLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLI

    DatePrice TargetRatingAnalyst
    8/10/2022$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2022Buy → Neutral
    BTIG Research
    8/10/2022$12.00 → $8.00Overweight → Neutral
    JP Morgan
    3/2/2022Outperform
    Cowen
    2/25/2022$20.00 → $14.00Equal-Weight
    Morgan Stanley
    2/15/2022$36.00 → $20.00Equal-Weight
    Morgan Stanley
    1/6/2022$61.00 → $12.00Buy → Hold
    Stifel
    1/6/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berkeley Lights downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously

      8/10/22 9:27:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by BTIG Research

      BTIG Research downgraded Berkeley Lights from Buy to Neutral

      8/10/22 7:24:20 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by JP Morgan with a new price target

      JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously

      8/10/22 6:23:47 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Financials

    Live finance-specific insights

    See more

    $BLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BLI
    SEC Filings

    See more
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

      EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

      2/13/23 4:30:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results

      EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

      1/9/23 4:02:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - Bruker Cellular Analysis, Inc. (0001689657) (Subject)

      2/8/24 5:58:45 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Berkeley Lights Inc.

      SC 13G - PhenomeX Inc. (0001689657) (Subject)

      8/28/23 5:04:18 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - PhenomeX Inc. (0001689657) (Subject)

      5/5/23 11:52:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Berkeley Lights Inc.

      15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/12/23 9:00:26 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form POSASR filed by Berkeley Lights Inc.

      POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:16:24 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Berkeley Lights Inc.

      S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:06:56 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Announces Appointment of Scott Chaplin as Chief Legal Officer

      EMERYVILLE, Calif., Sept. 19, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately. Mr. Chaplin will have overall responsibility for the corporate legal function, including contracts, governance, compliance and management of its extensive intellectual property and patent portfolio. As chief legal officer, he will serve as an adviser to the chief executive officer (CEO), Board of Directors, and senior management members.

      9/19/22 8:43:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

      EMERYVILLE, Calif., Aug. 1, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Rolando Brawer, Ph.D. has been named executive vice president, Strategy & Corporate Development, effective immediately. In this newly created role, Dr. Brawer will lead Berkeley Lights' strategy and corporate development functions and support the Company's growth strategy through identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, joint ventures and more. "We are thrilled to welco

      8/1/22 8:35:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:42:49 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:41:09 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:32:22 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care